11P - Mammographic density change and risk of breast cancer
Authors
- Shadi Azam (Stockholm, Sweden)
- Mikael Eriksson (Stockholm, Sweden)
- Arvid Sjölander (Stockholm, Sweden)
- Roxanna Hellgren (Stockholm, Sweden)
- Marike Gabrielson (Stockholm, Sweden)
- Kamila Czene (Stockholm, Sweden)
- Per Hall (Stockholm, Sweden)
Speakers
- Shadi Azam (Stockholm, Sweden)
12P - Ductal carcinoma in situ of the breast: Immune cell composition according to subtype
Authors
- Marie Colombe Agahozo (Rotterdam, Netherlands)
- Mieke R. Van Bockstal (Woluwe-Saint-Lambert, Belgium)
- Floris H. Groenendijk (Rotterdam, Netherlands)
- Thierry P. Van den Bosch (Rotterdam, Netherlands)
- Pieter Westenend (No City Provided, Namibia)
- Carolien H. Van Deurzen (Rotterdam, Netherlands)
Speakers
- Marie Colombe Agahozo (Rotterdam, Netherlands)
14P - Outcomes of women at high familial risk for breast cancer in Australia: An 8-year single-centre experience
Authors
- Jacqueline Lammert (Munich, Germany)
- Anita R. Skandarajah (Melbourne, Australia)
- Kylie Shackleton (Melbourne, Australia)
- Patricia Calder (Melbourne, Australia)
- Susan Thomas (Melbourne, Australia)
- Geoffrey J. Lindeman (Melbourne, Australia)
- G. Bruce Mann (Melbourne, Australia)
Speakers
- Jacqueline Lammert (Munich, Germany)
15P - Influence of PIK3CA mutations on breast cancer proliferation, lymphocyte infiltration and clinical outcome: Pooled analysis of 484 patients from three prospective multicentre GBG trials
Authors
- Paul Jank (Marburg, Germany)
- Sibylle Loibl (Neu-Isenburg, Germany)
- Peter A. Fasching (Erlangen, Germany)
- Thomas Karn (Frankfurt am Main, Germany)
- Frederik Marmé (Heidelberg, Germany)
- Volkmar Mueller (Hamburg, Germany)
- Christian Schem (Hamburg, Germany)
- Elmar Stickeler (Aachen, Germany)
- Bianca Lederer (Neu-Isenburg, Germany)
- Carsten Denkert (Marburg, Germany)
Speakers
- Paul Jank (Marburg, Germany)
16P - Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer
Authors
- Yunyun Niu (Shanghai, China)
- Binliang Liu (Beijing, China)
- Chunxiao Li (Beijing, China)
- Lixi Li (Beijing, China)
- Zongbi Yi (Beijing, China)
- Xiaoying Sun (Beijing, China)
- Hongyan Chen (Beijing, China)
- Fei Ma (Beijing, China)
- Sijia Lu (Shanghai, China)
Speakers
- Xiuwen Guan (Beijing, China)
17P - Are single hormone receptor-positive phenotypes biologically and clinically distinct breast cancer? A population-based study
Authors
- Yunhai Li (Chongqing, China)
- Yushen Wu (Chongqing, China)
- Dejuan Yang (Chongqing, China)
- Hongzhong Li (Chongqing, China)
- Guosheng Ren (Chongqing, China)
Speakers
- Yunhai Li (Chongqing, China)
18P - Secondary mechanisms of anti-HER2 resistance in breast cancer: NF1 as an actionable target
Authors
- Bruno A. Duso (Milan, PA, Italy)
- Claudia Poletti (Milan, Italy)
- Giuseppe Curigliano (Milan, Italy)
- Pier G. Pelicci (Milan, Italy)
- Luca Mazzarella (Milan, Italy)
Speakers
- Bruno A. Duso (Milan, PA, Italy)
19P - The clinical impact of substituting multigene assays: Comparative clinical analysis of PAM50-ROR versus 21-gene assay
Authors
- Christos J. Markopoulos (Athens, Greece)
- Louis Hochheiser (Burlington, United States of America)
- John Hornberger (Redwood City, United States of America)
- Evangelos Hytopoulos (Redwood City, United States of America)
- Melissa C. Stoppler (Redwood City, United States of America)
- Matthew Gitlin (Los Angeles, United States of America)
Speakers
- Christos J. Markopoulos (Athens, Greece)
20P - ERBB2 mRNA as predictor of response to anti-HER2 antibody-drug conjugates (ADC) in breast cancer (BC)
Authors
- Gaia Griguolo (Bellinzona, Switzerland)
- Fara Brasó-Maristany (Barcelona, Spain)
- Tomás Pascual (Barcelona, Spain)
- Nuria Chic (Barcelona, Spain)
- Maria Vidal (Barcelona, Spain)
- Barbara Adamo (Barcelona, Spain)
- Tommaso Giarratano (Padova, Italy)
- Maria Vittoria Dieci (Padova, Italy)
- Valentina Guarneri (Padova, Italy)
- Aleix Prat (Barcelona, Spain)
Speakers
- Gaia Griguolo (Bellinzona, Switzerland)
25P - Expression of ER, PR, HER2 and Ki67 in the neoadjuvant GeparX trial: Comparison of central immunohistochemistry with an automated cartridge-based system for mRNA assessment (on behalf of the GBG neoadjuvant and translational subboard)
Authors
- Carsten Denkert (Marburg, Germany)
- Paul Jank (Marburg, Germany)
- Theresa Link (Dresden, Germany)
Speakers
- Carsten Denkert (Marburg, Germany)
30P - Update on the phase II SUMMIT trial: Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer
Authors
- Lillian M. Smyth (Dublin, Ireland)
- Cristina Saura (Barcelona, Spain)
- Sarina A. Piha-Paul (Houston, United States of America)
- Janice Lu (Los Angeles, United States of America)
- Ingrid A. Mayer (Nashville, United States of America)
- Adam M. Brufksy (Pittsburgh, United States of America)
- Iben Spanggaard (Copenhagen, Denmark)
- Monica Arnedos (Villejuif, France)
- Richard E. Cutler (South San Francisco, United States of America)
- David M. Hyman (New York, United States of America)
Speakers
- Lillian M. Smyth (Dublin, Ireland)
33P - Germline PALB2 heterozygous mutations in breast cancers: Haploinsufficiency paradigm
Authors
- Quchang Ouyang (Changsha, China)
- Zhe-Yu Hu (Changsha, China)
- Liping Liu (Changsha, China)
- Jianxiang Gao (Changsha, China)
- Hui Wu (Changsha, China)
- Jun Lu (Changsha, China)
- Ning Xie (Changsha, China)
- Can Tian (Changsha, China)
- Zhentian Liu (Beijing, China)
- Yaping Xu (Beijing, China)
Speakers
- Quchang Ouyang (Changsha, China)